Rockefeller Capital Management L.P. Cuts Stake in Sanofi $SNY

Rockefeller Capital Management L.P. lessened its stake in Sanofi (NASDAQ:SNY) by 5.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 370,181 shares of the company’s stock after selling 20,928 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Sanofi were worth $17,883,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Voya Investment Management LLC lifted its stake in shares of Sanofi by 11.6% in the first quarter. Voya Investment Management LLC now owns 206,635 shares of the company’s stock worth $11,460,000 after buying an additional 21,540 shares in the last quarter. Ascent Group LLC purchased a new position in Sanofi in the 1st quarter worth approximately $426,000. 1248 Management LLC purchased a new position in Sanofi in the 1st quarter worth approximately $518,000. Equity Investment Corp lifted its position in Sanofi by 2.5% in the 2nd quarter. Equity Investment Corp now owns 2,512,435 shares of the company’s stock valued at $121,376,000 after acquiring an additional 62,109 shares in the last quarter. Finally, Simon Quick Advisors LLC purchased a new stake in Sanofi during the 2nd quarter valued at $246,000. Institutional investors own 14.03% of the company’s stock.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $50.66 on Wednesday. The firm’s 50 day moving average price is $49.16 and its 200-day moving average price is $49.35. Sanofi has a twelve month low of $44.62 and a twelve month high of $60.12. The company has a quick ratio of 0.94, a current ratio of 1.06 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $124.40 billion, a PE ratio of 11.86, a price-to-earnings-growth ratio of 1.38 and a beta of 0.49.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 24th. The company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.10. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The company had revenue of $14.53 billion during the quarter, compared to analyst estimates of $12.62 billion. During the same period in the previous year, the business posted $2.25 earnings per share. The firm’s quarterly revenue was down 7.5% compared to the same quarter last year. Equities research analysts expect that Sanofi will post 4.36 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a report on Tuesday, November 11th. Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $56.00 to $58.00 in a research report on Monday, September 8th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Finally, JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $62.67.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.